Powerhouses of the cells: Mitochondria have a waste disposal mechanism to get rid of mutated mtDNA

In many tissues, mutations in mtDNA accumulate as a result of normal aging. These kinds of mutations are an important cause of many aging-associated diseases. There are thousands of copies mtDNA in every cell, so mitochondrial function is only impaired when the percentage of mutated mtDNA molecules exceeds a certain threshold value. It has long been established that mitochondrial damage, including acute mtDNA damage, triggers the process of mitophagy. In this process, dysfunctional mitochondrial parts are selectively degraded and recycled.

Dr David Pla-Martin, the lead author of the current study, explained the details: 'What is new in our study is that this mechanism does not affect the cells' endowment with mitochondria, but only clears out the damaged mtDNA. By labelling neighbouring proteins -- so-called proximity labelling -- we showed that mtDNA damage leads to the recruitment of endosomes in close proximity to nucleoids.' Their removal is coordinated by the interaction of the nucleoid protein Twinkle and the mitochondrial membrane proteins SAMM50 and ATAD3. ATAD3 controls their distribution, SAMM50 induces the release and transfer of the nucleoid to the so-called endosomes. 'This additionally prevents the activation of an immune response. The protein VPS35, the main component of the retromer, mediates the maturation of early endosomes into late autophagy vesicles, where degradation and recycling ultimately take place,' said Pla-Martin.

Using a mouse model in which mtDNA mutations lead to impaired muscle regeneration, the scientists also showed that selectively mutated mtDNA can be removed by stimulating the activity of the autophagy mechanism with rapamycin. The total number of mtDNA copies thus remains constant, preserving mitochondrial function.

Group leader Professor Dr Rudolf Wiesner added: 'Mutations in the genes that code for these proteins lead to severe neurological diseases, in VPS35 for example Parkinson's disease. We now want to use these proteins as new molecular targets to open up entirely new treatment options for these kinds of aging-associated diseases.' Although the road to therapeutic application could still be long, the research team sees a promising approach here.